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Introduction:
Electrolytes disorders are a common finding in
patients with End stage liver disease (ESLD). Liver
transplantation (OLT) is frequently associated with
massive transfusion and fluid shifts in patients with
renal dysfunction, and management of hyponatremla,
hyperkalemia and hypervolemia are major concerns for
anesthesiologists. This case describes a multimodal
approach in treatment of combined severe
hyponatremla, hyperkalemia and hypervolemia.
Case Description:
A patient for Liver Transplant was found to be
hyponatremic (118 mM/L), hyperkalemic (6.9mM/L), and
uremic (BUN/Cr = 95/2.6) preoperatively (Fig 1). OLT
was proceeded not to loose a small window of
opportunity, although potential complications were
recognized (1).

However, sodium bicarbonate was used once at reperfusion
for rapid correction of acidosis. The treatment was

successful. Sequelae of hyperkalemia were avoided even
during reperfusion and Na level was not increased more
than 10mM/L intraoperatively. He remains free of central
pontine myelinolysis eight months postoperatively.
Discussion:
Hyponatremla is a strong predictor of wait-list mortality,
and is associated with worse post-transplant outcomes.
Treatment of hyponatremia is very difficult especially given
the risk of central pontine myelinolysis . Table 1 shows the
content of sodium in typical fluids administered during OLT.
Table 1: Sodium content in different solutions
Solution

THAM E®a

NaBicarb 8,4%
Saline 0,9%
Plasmalyte
FreshFrozenPlasma

Albumin 5%

To correct hyperkalemia, dextrose 50%(200 ml) and
insulin (40 units) were given, his own phlebotomized
blood (1.5L) and homologous blood (2units) were washed
using an autotransfusion system before reinfusion, and
continuous venovenous hemodialysis (CVVH) was
instituted. To maintain a hyponatremic state,
tromethamine sulfate (THAM, 1000 mL)) was used to
treat metabolic acidosis instead of NaHCO3.

Na+ mEq/L
30
1000
154
140
172
145-160

K+ mEq/L
5
5
3.5
2

We chose THAM as our primary buffering agent for
treating acidosis because of it’s lack of sodium content.
Correcting the base deficit by THAM before reperfusion of
the graft liver may help to prevent the complications of
reperfusion (hyperkalemia, metabolic acidosis, and release
of myocardial depressant and vasoactive substances from
the donor liver). These metabolic derangements may
produce hypotension, bradycardia, arrhythmias, vascular
collapse or cardiac arrest.
A possible advantage of THAM is that it promptly enters the
hepatic intracellular space, where it exerts a buffering effect
and may protect hepatocytes against hypoxia. Correction of
acidosis with NaHCO3 in liver transplantation can limit
acidosis, but this frequently leads to hypercarbia,
hypernatremia and postoperative rebound alkalosis (4).
Hypernatremia caused by the sodium load of NaHCO3 might
burden the kidney and increase the risk of central pontine
myelinolysis

An advantage of sodium bicarbonate is that it can be
administered quickly.
In patients with renal impairment, hyperkalemia and
hypervolemia, CVVH can be performed on the hemodynamically
unstable patient, because infusion of a large amounts of blood
products such as packed red cells, plasma and platelets are
frequently required (5).
Intraoperative autotransfusion can reduce potassium load by
washing the shed blood with 0.9% saline in a cell-saver device, but
the washing process removes electrolytes, plasma, including
clotting factors, pharmacologic drugs, pro- and anti-inflammatory
factors, and platelets. Washing pRBCs before transfusion with a
continuous autotransfusion device can significantly reduce the
amount of potassium infused. One disadvantage of washing
pRBCs is the increased sodium and chloride levels and decreased
pH (6).
Conclusion:
A multimodal approach is required to treat electrolytes disorders
in patients with end-stage liver disease and renal dysfunction.
Unexpected severe hyponatremla was thought to be caused by acute
excessive water consumption after repeated paracentesis, but it is
possible he was developing hepatorenal syndrome. Because of his
risk for multiorgan failure and sepsis without OLT we proceeded.

The combination of CVVH, THAM and cell saver was able to
achieve a slow increase of sodium level (10 mg/h), avoiding CNS
dysfunction by CPM, and to correct Hyperkalemia.
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